In vitro and in vivo interactions between miltefosine and other antileishmanial drugs
about
Advances in Development of New Treatment for LeishmaniasisDevelopments in the treatment of visceral leishmaniasisMiltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasisResveratrol is active against Leishmania amazonensis: in vitro effect of its association with Amphotericin BMore efficient ways of assessing treatments for neglected tropical diseases are required: innovative study designs, new endpoints, and markers of effectsLeishmania donovani develops resistance to drug combinationsUsing a non-image-based medium-throughput assay for screening compounds targeting N-myristoylation in intracellular Leishmania amastigotesCombined treatment of miltefosine and paromomycin delays the onset of experimental drug resistance in Leishmania infantum.Water-soluble polymer-drug conjugates for combination chemotherapy against visceral leishmaniasis.Reductions in skin and systemic parasite burdens as a combined effect of topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) amazonensis.Antileishmanial and antitrypanosomal activities of the 8-aminoquinoline tafenoquine.Leishmaniasis: an update of current pharmacotherapy.Andrographolide nanoparticles in leishmaniasis: characterization and in vitro evaluations.Treatment options for visceral leishmaniasis.Paromomycin.Plants with anti-Leishmania activity: Integrative review from 2000 to 2011.An update on pharmacotherapy for leishmaniasisAntimony-resistant clinical isolates of Leishmania donovani are susceptible to paromomycin and sitamaquineHistone methyltransferase inhibitors are orally bioavailable, fast-acting molecules with activity against different species causing malaria in humansUse of antimony in the treatment of leishmaniasis: current status and future directions.Therapeutic switching in leishmania chemotherapy: a distinct approach towards unsatisfied treatment needs.Miltefosine: oral treatment of leishmaniasis.In vitro antileishmanial drug susceptibility of clinical isolates from patients with Indian visceral leishmaniasis--status of newly introduced drugsThe relationship between leishmaniasis and AIDS: the second 10 yearsEupomatenoid-5 Isolated from Leaves of Piper regnellii Induces Apoptosis in Leishmania amazonensis.Trans- β -Caryophyllene: An Effective Antileishmanial Compound Found in Commercial Copaiba Oil (Copaifera spp.).Phenotypic Screening In Vitro of Novel Aromatic Amidines against Trypanosoma cruzi.N-(2-hydroxypropyl)methacrylamide-amphotericin B (HPMA-AmB) copolymer conjugates as antileishmanial agents.Optimizing efficacy of Amphotericin B through nanomodification.Drug resistance in visceral leishmaniasis.Amiodarone and miltefosine act synergistically against Leishmania mexicana and can induce parasitological cure in a murine model of cutaneous leishmaniasis.Successful use of miltefosine and sodium stibogluconate, in combination, for the treatment of an HIV-positive patient with visceral leishmaniasis: a case report and brief review of the literature.TLR9 and MyD88 are crucial for the maturation and activation of dendritic cells by paromomycin-miltefosine combination therapy in visceral leishmaniasisIn vitro synergistic effect of amphotericin B and allicin on Leishmania donovani and L. infantum.Combination therapy with tamoxifen and amphotericin B in experimental cutaneous leishmaniasis.Visceral leishmaniasis: experimental models for drug discovery.Visceral leishmaniasis treatment: What do we have, what do we need and how to deliver it?Cutaneous leishmaniasis: therapeutic strategies and future directions.Interaction between miltefosine and amphotericin B: consequences for their activities towards intestinal epithelial cells and Leishmania donovani promastigotes in vitro.In vitro activities of hexaazatrinaphthylenes against Leishmania spp
P2860
Q28082097-FB92020A-3507-4370-B7D2-9D13E0522EFEQ28256441-8FFBB476-D77F-4C6D-B306-621274DFC71DQ28271849-258E0BC2-F48C-4C95-B559-20E5064C751BQ28395466-F7A645DC-D32E-4C53-96FF-D1F0DABDBCF3Q28483969-F513AD23-8021-4849-A84B-C69806E4C914Q28484463-8B1269B6-518B-4DA2-A7EF-14C8F311BC35Q28542767-D510B985-93E3-4A2C-A194-89625CEA774EQ33728704-0BF4204D-3DDC-4AAC-85D8-E0F29C5A5813Q33823803-434793D4-32EB-4A20-9576-46F37AA377B9Q34289958-6ADE213E-C853-4D65-86D5-EA91A24BECAAQ34309401-FD15EF02-31DB-4C7A-A76C-DF05731323C4Q34318765-AA6DD8F2-DEC5-4EE0-A05B-AE85A8DE5EEEQ34501958-5F80EB0E-06A3-4201-8FD8-C39C644EC647Q34510966-55210008-8622-41BD-B371-30039B91462AQ34864208-B27E3E3F-A7B4-4193-9C6F-B8B0564325B8Q34901330-D154D524-C6DC-4B54-8638-A6A36AD7B861Q34945204-00D784C2-21B6-4CA2-B5A3-92896D8EDD64Q35005213-699AED7D-66A8-4730-ACC6-45ECC163A286Q35105899-8EFFADE1-0D48-48C7-88C8-8C26ECFADCA3Q35377767-04334795-9ECC-4BD6-AF37-7D280C376C9FQ35606296-5CD0F9A3-E405-4929-A7D7-A1A0CEE7BAFDQ36441483-53E36BE0-2037-4E91-B3D5-E5795A907C19Q36450807-13E3E88A-426B-492B-A2E1-FBB33D1559ADQ36538814-551BDE27-17CF-4F82-94BC-4ECCE1C33A01Q36746345-3E2504E7-2064-49F0-9A3F-68627E8A0636Q36995829-DA274DBA-9C40-499B-9F55-1E5FD899794CQ37120187-DC0C3DE1-3218-422C-AC5F-773151E49E4EQ37159459-A7B8594A-004B-468E-8F64-E8E3324FCFAEQ37178176-E9EC2634-4370-47FA-986C-D5BBA5D156C0Q37407549-3D0B1769-78D6-451A-9D73-211B205EE88CQ37450724-FED3DD47-7965-4E74-A209-53D5442D8E9CQ37543667-BAB2ECEE-35A2-4F55-A10A-074757C7EBEEQ37635270-3AE373E4-3D88-46AB-B448-A49D30D28520Q37643719-EF4B421C-F324-40F5-B0F6-E01EE70AFFEBQ37712995-2380094A-834A-46BA-9293-FF794BFA9638Q37842069-DAF02506-D17D-4A47-925C-E5C929F58989Q38188571-167641C4-389A-4ED8-920B-3E8EC97D6025Q38872459-3F2C4D3A-3A96-40CA-833E-B2CA2072430FQ39078243-2D3B5092-4F69-4ACE-9667-BD959EA62F1AQ39196831-C9B8C37D-2365-47C6-9A92-54982DFE9A30
P2860
In vitro and in vivo interactions between miltefosine and other antileishmanial drugs
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
name
In vitro and in vivo interactions between miltefosine and other antileishmanial drugs
@ast
In vitro and in vivo interactions between miltefosine and other antileishmanial drugs
@en
In vitro and in vivo interactions between miltefosine and other antileishmanial drugs
@nl
type
label
In vitro and in vivo interactions between miltefosine and other antileishmanial drugs
@ast
In vitro and in vivo interactions between miltefosine and other antileishmanial drugs
@en
In vitro and in vivo interactions between miltefosine and other antileishmanial drugs
@nl
prefLabel
In vitro and in vivo interactions between miltefosine and other antileishmanial drugs
@ast
In vitro and in vivo interactions between miltefosine and other antileishmanial drugs
@en
In vitro and in vivo interactions between miltefosine and other antileishmanial drugs
@nl
P2860
P1476
In vitro and in vivo interactions between miltefosine and other antileishmanial drugs
@en
P2093
Karin Seifert
Simon L Croft
P2860
P356
10.1128/AAC.50.1.73-79.2006
P407
P577
2006-01-01T00:00:00Z